LYKA LABS
Lyka Labs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in LYKA LABS
Start SIPLyka Labs Share Price
Lyka Labs Investment Rating
-
Master Rating:
-
Lyka Labs has an operating revenue of Rs. 123.78 Cr. on a trailing 12-month basis. An annual revenue growth of 123% is outstanding, Pre-tax margin of 31% is great, ROE of 292% is exceptional. The company has a high debt to equity of 463%, which can be a reason to worry. The stock from a technical standpoint is trading close to its key moving averages, around 4% and 0% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 18% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 9 which is a GOOD score indicating consistency in earnings, a RS Rating of 25 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 112 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
|---|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 22 | 22 | 28 | 28 | 65 | 43 | 18 |
| Operating Expenses Qtr Cr | 17 | 16 | 16 | 16 | 21 | 14 | 12 |
| Operating Profit Qtr Cr | 5 | 6 | 12 | 12 | 44 | 30 | 5 |
| Depreciation Qtr Cr | 3 | 3 | 9 | 2 | 2 | 2 | 2 |
| Interest Qtr Cr | 3 | 3 | 3 | 5 | 6 | 7 | 6 |
| Tax Qtr Cr | 0 | 0 | 13 | 0 | 6 | 2 | -4 |
| Net Profit Qtr Cr | 0 | 0 | -15 | 6 | 30 | 20 | 0 |
Lyka Labs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- 134.11
- 50 Day
- 133.25
- 100 Day
- 133.72
- 200 Day
- 132.92
- 20 Day
- 132.06
- 50 Day
- 132.06
- 100 Day
- 133.19
- 200 Day
- 136.09
Lyka Labs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 140.2 |
| Second Resistance | 143.2 |
| Third Resistance | 147.5 |
| RSI | 50.15 |
| MFI | 75.78 |
| MACD Single Line | 1.02 |
| MACD | 1.21 |
| Support | |
|---|---|
| First Resistance | 132.9 |
| Second Resistance | 128.6 |
| Third Resistance | 125.6 |
Lyka Labs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 172,902 | 5,840,630 | 33.78 |
| Week | 86,798 | 3,866,833 | 44.55 |
| 1 Month | 140,307 | 7,013,942 | 49.99 |
| 6 Month | 185,616 | 9,076,626 | 48.9 |
Lyka Labs Result Highlights
Lyka Labs Synopsis
NSE-Medical-Generic Drugs
Lyka Labs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 164.35 Cr. and Equity Capital is Rs. 28.69 Cr. for the Year ended 31/03/2022. Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738.| Market Cap | 384 |
| Sales | 100 |
| Shares in Float | 1.49 |
| No of funds | 18 |
| Yield |
| Book Value | 8.64 |
| U/D Vol ratio | 1.2 |
| LTDebt / Equity | 137 |
| Alpha | -0.08 |
| Beta | 1.03 |
Lyka Labs
| Owner Name | Sep-22 | Jun-22 | Mar-22 | Dec-21 |
|---|---|---|---|---|
| Promoters | 47.59% | 47.8% | 47.79% | |
| Mutual Funds | 3.54% | 3.54% | 0.73% | |
| Insurance Companies | 0.46% | 0.46% | 0.46% | |
| Foreign Portfolio Investors | 0.57% | 0.76% | 1.12% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 37.72% | 38.85% | 37.26% | |
| Others | 10.12% | 8.59% | 12.64% |
Lyka Labs Management
| Name | Designation |
|---|---|
| Mr. Kunal N Gandhi | Chairman & M.D & CEO |
| Mr. Yogesh B Shah | Executive Director & CFO |
| Mrs. Nehal N Gandhi | Non Executive Director |
| Mr. Vinod S Shanbhag | Independent Director |
| Mr. Sandeep P Parikh | Independent Director |
| Mrs. Dhara P Shah | Independent Director |
Lyka Labs Forecast
Price Estimates
Lyka Labs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-11-09 | Quarterly Results | |
| 2022-08-08 | Quarterly Results & Amalgamation | |
| 2022-05-20 | Audited Results | |
| 2022-01-20 | Quarterly Results | |
| 2021-10-29 | Quarterly Results |
Lyka Labs FAQs
What is Share Price of Lyka Labs ?
Lyka Labs share price is ₹133 As on 10 December, 2022 | 08:36
What is the Market Cap of Lyka Labs ?
The Market Cap of Lyka Labs is ₹383.9 Cr As on 10 December, 2022 | 08:36
What is the P/E ratio of Lyka Labs ?
The P/E ratio of Lyka Labs is -43.8 As on 10 December, 2022 | 08:36
What is the PB ratio of Lyka Labs ?
The PB ratio of Lyka Labs is 28.5 As on 10 December, 2022 | 08:36